REspiratorySyncytial Respiratory virus Consortium in EUrope

Budget: €25M (IMI funding programme)
Duration: 2017-2021
Participants: 18 partners
Coordinator: University of Edinburgh

As partners of RESCEU, we are involved in the fight against RSV, a disease that affects 33 million children
yearly and causes 118,000 deaths and for which there is no specific treatment yet. Currently, most drug
development efforts are directed to prevention and immunisation.
The RESCEU project is developing robust evidence on RSV disease burden and economic impact; create a
sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health,
scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to
perform future pivotal trials for RSV vaccines and therapeutics.